Intracellular Trafficking of Neuropeptide Y Receptors

Mörl, Karin; Beck‐Sickinger, Annette G.

doi:10.1016/bs.pmbts.2015.02.011

Cited by 7 publications

(4 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the internalization process for the hY 5 R is relatively slow, the other Y-receptors internalize rapidly within few minutes (Gicquiaux et al, 2002 ). The recycling of the hY 1 R and hY 2 R back to the cell membrane has been observed by fast and slow endosomal routes (Gicquiaux et al, 2002 ; Mörl and Beck-Sickinger, 2015 ). These recycling processes are essential for an active drug accumulation inside the cell.…”

Section: Peptide Receptors As Targets In Cancer Therapymentioning

confidence: 99%

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies

2020

Self Cite

View full text Add to dashboard Cite

Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.

show abstract

Section: Peptide Receptors As Targets In Cancer Therapymentioning

confidence: 99%

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recycling of the hY 1 R and hY 2 R back to the plasma membrane has been observed via fast and slow endosomal routes. [ 111,112 ]…”

Section: Targeting Of New G Protein‐coupled Receptorsmentioning

confidence: 99%

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

2020

View full text Add to dashboard Cite

Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer therapies that offer the potential to selectively destroy malignant cells, while sparing healthy tissue. Thus, undesired side-effects in tumor patients are highly reduced. Peptide-binding receptors are frequently overexpressed on cancer cells and therefore promising targets for selective tumor therapy. In this review, peptidebinding receptors for anti-cancer drug delivery are summarized with a focus on peptide ligands as delivery agents. In the first part, some of the most studied peptidebinding receptors are presented, and the ghrelin receptor and the Y 1 receptor are introduced as more recent targets for cancer therapy. Furthermore, nonpeptidic small molecules for receptor targeting on cancer cells are outlined. In the second part, peptide conjugates for the delivery of therapeutic cargos in cancer therapy are described.The essential properties of receptor-targeting peptides are specified, and recent developments in the fields of classical peptide-drug conjugates with toxic agents, radiolabeled peptides for radionuclide therapy, and boronated peptides for boron neutron capture therapy are presented. K E Y W O R D SBNCT, G protein-coupled receptor, internalization, peptide drug conjugate, tumor targeting

show abstract

“…Recent studies have shown that NPY participates in many physiological and psychological processes, such as inhibition of vascular smooth muscle contraction and alleviation of anxiety and depression[ 16 , 17 ]. Till now, five primary NPY receptors (Y1R, Y2R, Y4R, Y5R, and y6R) have been found in mammals, and all of them belong to the superfamily of G protein-coupled receptors[ 18 ]. Different receptors are distributed differently in the human body, play different biological functions, and have different affinities for NPY (Y2R > Y1R > Y5R, Y4R = y6R)[ 19 ].…”

Section: Npy and Receptorsmentioning

confidence: 99%

Mechanisms of action of neuropeptide Y on stem cells and its potential applications in orthopaedic disorders

Wu¹,

Jiang²,

Yu³

2020

WJSC

View full text Add to dashboard Cite

Musculoskeletal disorders are the leading causes of disability and result in reduced quality of life. The neuro-osteogenic network is one of the most promising fields in orthopaedic research. Neuropeptide Y (NPY) system has been reported to be involved in the regulations of bone metabolism and homeostasis, which also provide feedback to the central NPY system via NPY receptors. Currently, potential roles of peripheral NPY in bone metabolism remain unclear. Growing evidence suggests that NPY can regulate biological actions of bone marrow mesenchymal stem cells, hematopoietic stem cells, endothelial cells, and chondrocytes via a local autocrine or paracrine manner by different NPY receptors. The regulative activities of NPY may be achieved through the plasticity of NPY receptors, and interactions among the targeted cells as well. In general, NPY can influence proliferation, apoptosis, differentiation, migration, mobilization, and cytokine secretion of different types of cells, and play crucial roles in the development of bone delayed/non-union, osteoporosis, and osteoarthritis. Further basic research should clarify detailed mechanisms of action of NPY on stem cells, and clinical investigations are also necessary to comprehensively evaluate potential applications of NPY and its receptor-targeted drugs in management of musculoskeletal disorders.

show abstract

Intracellular Trafficking of Neuropeptide Y Receptors

Cited by 7 publications

References 111 publications

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Mechanisms of action of neuropeptide Y on stem cells and its potential applications in orthopaedic disorders

Contact Info

Product

Resources

About